Add to ORKGWe recently showed that Nebivolol, a [beta]-adrenergic receptor (AR) antagonist attenuates myocardial oxidative stress and promotes insulin metabolic signaling in 9 week old Zucker obese (ZO) insulin resistant rats. Here, we demonstrate that Nebivolol suppresses angiotensin II type I receptor (AT1R)-mediated signaling in ZO hearts as well as in HL-1 cardiomyocytes
Objectives: Most b-blockers may induce weight gain, dysglycemia, and dyslipidemia. Nebivolol is a th...
Nebivolol is a cardioselective beta-blocker (BB) currently used for the treatment of hypertension. I...
Recent evidence suggests that blockade of the renin-angiotensin system ameliorates diabetes-induced ...
Abstract—Insulin resistance is associated with obesity and may be accompanied by left ventricular di...
BACKGROUND: Although effective in reducing blood pressure, therapy with a first-generation [beta]-bl...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
OBJECTIVE: Resistance to obesity is observed in rodents and humans treated with rapamycin (Rap) or n...
AbstractHypertension induces left-ventricular hypertrophy (LVH) by mechanisms involving oxidative st...
<div><p>Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has b...
In order to determine differences in cardiovascular cell response during nutrient stress to differen...
Background/Aims: Extensive research has explored the role of aldosterone in insulin resistance. Rece...
AbstractObjectivesWe tested the hypothesis that angiotensin II type 1 receptor blocker (ARB) may imp...
Background: Although obesity has been associated with metabolic and cardiac disturbances, the carrie...
BACKGROUND: Impaired myocardial beta-adrenergic receptor (betaAR) signaling, including desensitizati...
BACKGROUND: Although obesity has been associated with metabolic and cardiac disturbances, the carrie...
Objectives: Most b-blockers may induce weight gain, dysglycemia, and dyslipidemia. Nebivolol is a th...
Nebivolol is a cardioselective beta-blocker (BB) currently used for the treatment of hypertension. I...
Recent evidence suggests that blockade of the renin-angiotensin system ameliorates diabetes-induced ...
Abstract—Insulin resistance is associated with obesity and may be accompanied by left ventricular di...
BACKGROUND: Although effective in reducing blood pressure, therapy with a first-generation [beta]-bl...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
OBJECTIVE: Resistance to obesity is observed in rodents and humans treated with rapamycin (Rap) or n...
AbstractHypertension induces left-ventricular hypertrophy (LVH) by mechanisms involving oxidative st...
<div><p>Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has b...
In order to determine differences in cardiovascular cell response during nutrient stress to differen...
Background/Aims: Extensive research has explored the role of aldosterone in insulin resistance. Rece...
AbstractObjectivesWe tested the hypothesis that angiotensin II type 1 receptor blocker (ARB) may imp...
Background: Although obesity has been associated with metabolic and cardiac disturbances, the carrie...
BACKGROUND: Impaired myocardial beta-adrenergic receptor (betaAR) signaling, including desensitizati...
BACKGROUND: Although obesity has been associated with metabolic and cardiac disturbances, the carrie...
Objectives: Most b-blockers may induce weight gain, dysglycemia, and dyslipidemia. Nebivolol is a th...
Nebivolol is a cardioselective beta-blocker (BB) currently used for the treatment of hypertension. I...
Recent evidence suggests that blockade of the renin-angiotensin system ameliorates diabetes-induced ...